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Available online 11 August 2018This study was aimed at improving dissolution rate and sustained release of progesterone by varying copolymer
composition and polymer: drug ratio of PLGA. Drug-loaded particles were prepared using electrohydrodynamic
atomization. The effects of polymer: drug ratio and copolymer composition on particle properties and in vitro
drug-release proﬁle were investigated. The physical form of the generated particles was determined via X-ray
powder diffraction (XRPD) and Fourier transform infrared spectroscopy (FTIR). Drug release in vitro was found
to be dependent on copolymer composition, where the release rate increased with decreased lactide content
of PLGA. Particles produced with solutions of copolymer (75:25) had elongated shapes. In general, the obtained
results indicated that the prepared microparticles were ideal carriers for oral administration of progesterone of-
fering great potential to improve the dissolution rate of drugs that suffer from low aqueous solubility.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
Electrohydrodynamic
Progesterone
Mathematical modelling
Drug delivery system1. Introduction
In the development of oral formulations, the aqueous solubility of the
drug plays a key role in the extent of drug absorption [1]. For any thera-
peutics to be successfully absorbed in the body, it needs to be present inhe).
. This is an open access article underthe form of an aqueous solution at the desired site of action [1,2]. The sol-
ubility is the limiting factor for a drug to attain the desired concentration
in systemic circulation in order to achieve pharmacological response for
an orally administered drug [3]. However, many drug molecules under
development are poorly soluble: that critically limits their absorption,
resulting in poor bioavailability and pharmacokinetics in vivo [2,3].
Progesterone is an endogenous steroidal hormone that is involved in
all aspects of reproduction and used to control reproductive function. Itthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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women, who failed to ovulate and stop producing progesterone from
their ovaries [4], this would drop down the hormone levels in the
body, hence results in various effects such as hot ﬂashes and night
sweats. In addition, recent studies have reported the applicability of
progesterone in preventing preterm birth. This is deﬁned by World
Health Organization as birth before 37 weeks of pregnancy are com-
pleted [5], which is the largest cause of neonatal morbidity and mortal-
ity in infants [6,7]. Progesterone has an essential role in maintaining
pregnancy [8,9], and it is involved in establishing uterine quiescence
[10]. The various administration routes of progesterone include oral, pa-
rental (intramuscular and subcutaneous) and topical (as a creamof vag-
inal gel), of which peroral delivery is the most preferred route of
administration. However, progesterone suffers from a short half-life
and low water solubility; these lead to inconsistent bioavailability and
high ﬁrst pass metabolism [11]. Biodegradable polymers are promising
candidates for oral drug delivery with their ability to shield the drug
from external harsh chemical and enzymatic degradation of the gastro-
intestinal tract (GIT) aswell as bypass the ﬁrst passmetabolism through
their unique uptake mechanism [12,13]. A previous study reveals that
the dissolution rate of poorlywater-soluble drug can be enhanced by in-
corporating it into a polymeric matrix thereby inducing its amorphous
state [14], again making this a preferable oral delivery technique. In ad-
dition to this, long term sustained drug delivery systems can also be ob-
tained using biodegradable particles, in which progesterone can be
administered via depot injection [15] and released for a prolonged pe-
riod of time. In a depot injection, the medication is deposited in a local-
ized mass via intramuscularly, subcutaneously or intradermal injection.
This offers advantages over long-term daily injection which can com-
promise patient compliance.
Biodegradable microparticles in the ﬁeld of controlled drug release,
where the drug is continuously released from the particles within a pe-
riod of time, have generated immense interest. They are able to deliver a
wide range of drugs through various administration routes and enhance
drug bioavailability and protect the drug from degradation [16]. The
drug release behavior can be controlled by altering polymer composi-
tions includingmolecularweight,monomers ratio and the nature of ter-
minal groups for copolymers [17]. It has been reported that other than
the physicochemical properties of polymers, factors such as particle
size [18,19], morphology and porosity [20], as well as drug loading
[21] also play important roles in deciding the drug release kinetics. Ap-
propriate selection of the biodegradable polymericmaterials is essential
to develop a successful particulate delivery system. Among the variety
of materials available to fabricate these solid particles, copolymers
have receivedmuch attention in recent years as different physicochem-
ical properties can be achieved by altering their polymer composition.
Poly (D, L lactic co glycolic acid) (PLGA) is one of themost frequently
used biodegradable polymers in drug delivery applications [22,23].
PLGA is approved by the FDA as a drug delivery vehicle and it preferred
for this purpose because of its favorable biodegradability, biocompati-
bility and tunable physicochemical properties [24,25]. The copolymers
with various molecular weights and copolymer compositions are com-
mercially available. The ability to alter lactide: glycolide ratio, molecular
weight and the nature of terminal groups enables precise control over
drug release proﬁle [25]. In general, therapeutics can be orally released
in a controlled manner via transport through the polymer or be trig-
gered in response to environmental stimuli or released during polymer
dissolution [26]. In addition, the bioavailability of hydrophobic drugs
can be improved due to the hydrophilic property of PLGA, thus enhanc-
ing oral bioavailability [27,28].
Polymeric micro- and nanoparticles can be administered as oral, in-
jectable and inhalable drug delivery systems, and can be fabricated
using various methods including solvent evaporation [29], emulsion
[30,31], spray-drying [32,33], porous glass membrane emulsiﬁcation
[34] and coacervation [35]. However, most of these conventional ap-
proaches suffer from some limitations such as broad particle-sizedistribution, low drug encapsulation efﬁciency [36], particle agglomera-
tion and difﬁculties for incorporation of hydrophilic drugs [30,37].
Moreover, non-degradable surfactants are employed in some of the ap-
proaches whichmight cause unwanted effects in pharmaceutical appli-
cations. In addition, for highly sensitive and active pharmaceutical
ingredients, inactivation or degradation is possible owing to high tem-
perature, organic solvent exposure and high shear stress during the par-
ticle fabrication process [31,38]. Electrohydrodynamic atomization
(EHDA), also known as the electrospray technique, is believed to over-
come the drawbacks associated with conventional techniques and has
been deliberately chosen as a method for the fabrication of bioactive
molecule loaded micro and nanostructured materials in the application
of drug delivery [39–41]. In this method, drug molecules are ﬁrstly in-
corporated into the polymer solution and infused through a capillary
nozzle. A high voltage is applied to atomize the solution and the electric
charge generated on the droplet, competing with the surface tension
and resulting in near-monodisperse microdroplets in the cone-jet
mode and further solidify to formmicrospheres in a single-step process.
EHDA also has the potential to avoid particle aggregation due to self-
dispersing of the droplets owing to Coulombic repulsion [42].Moreover,
electrospraying has the advantage of high drug encapsulation efﬁciency
[43] and can enable encapsulation of both hydrophobic and hydrophilic
drugs [28,39].
In this work, electrospraying was utilized to produce progesterone
loaded PLGA particles. Many studies have investigated the formulations
of PLGA particles for controlled release of different pharmaceuticals
[16,18,25,43,44] and encapsulated hydrophobic drugs within different
polymer matrices [11,27,28]. Progesterone-loaded PLGA microparticles
have been prepared by several researchers by use of different
techniques, includingmicroﬂuidic [26], hydrogel template [45] and sol-
vent evaporation-based methods [46]. However, there is a lack of sys-
tematic reports on applying single step electrospraying in producing
progesterone-loaded particles, speciﬁcally using PLGA copolymer with
differentmonomers ratios and concentrationswhich can provide differ-
ent drug release proﬁle in order to meet various requirements of drug
delivery. Given the hydrophobicity of progesterone and that oral deliv-
ery is the most preferred route of administration, a particular challenge
and objective was to enhance its dissolution by incorporation of the
drug into the PLGA matrix. The overall objective of this study was to
carry out a systematic investigation on the effects of the electrospraying
technique, polymer concentration and use of two different copolymer
compositions (PLA/PGA ratio of 50:50 and 75:25) on the resulting par-
ticle properties, and release behavior (in vitro) using progesterone.
2. Material and methods
2.1. Materials
PLGAs with different copolymer ratios (1. PURASORB PDLG 5002A,
50:50 DL-lactide/glycolide copolymer, molecular weight of 17,000 Da,
inherent viscosity 0.2 dl g−1; 2. PURASORB PDLG 7502A, 75:25 DL-
lactide/glycolide copolymer, molecular weight of 17,000 Da, inherent
viscosity 0.2 dl g−1) was obtained from Corbion (Amsterdam, The
Netherlands). Progesterone (molecular weight of 314.46 g mol−1) and
N, N Dimethylacetamide (DMAc, anhydrous, 99.8%) were obtained
from Sigma-Aldrich (Poole, UK).
2.2. Particle preparation
Progesterone-loaded PLGA particles were produced using
electrospraying (Fig. 1). PLGA solutions with different concentrations
(2 and 4wt%) and copolymer formulations (50:50 and 75:25)were pre-
pared by dissolving the polymer in DMAc at ambient temperature
(20°C). Progesterone (2 mg/ml) was added to polymer solution at
each concentration to make polymer/drug ratios of 20:1 and 10:1.
Fig. 1. Electrohydrodynamic atomization setup.
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pared as a control study.
The polymer solutions were loaded into a 10 ml plastic syringe and
fed into a stainless-steel needle with internal diameter of 0.84 mm at
a constant ﬂow rate implemented by a syringe pump (Harvard PHD
4400, Edenbridge, UK). A high positive electrical potential varying
from 12.0 to 16.0 kV relative to the ground was supplied using a high
voltage power supply (Glassman Europe Ltd., UK). Once the droplets
were ejected from the stable cone-jet, particles were collected at a
working distance of 200mmbelow the needle exit, either on a glassmi-
croscope slide, or a grounded collector. The cone-jet formed at the tip of
the needle during particle production was monitored using a Leica
DMS300 camera. All experiments were conducted at ambient tempera-
ture (20 °C) and relative humidity of 40–55%. Each experiment was re-
peated 3 times.
2.3. Characterization of solutions
The density (ρ) was measured using a standard density bottle (DIN
ISO 3507-Gray-Lussac). Surface tensions (γ) of all the solutions were
determined usingWilhelmy's plate method using a Kruss tensionmeter
(Tensiometer K9, Hamburg, Germany). The viscosity (μ) was estimated
using a U-tube viscometer (VWR, size E). The electrical conductivity (κ)
was measured using a conductivity probe (Jenway 3540 pH/conductiv-
ity meter). The characterization of all solutions was undertaken atTable 1
Physicochemical characteristics of the solutions used for particle formation. In the case of visco
Formulation Polymer concentration and drug loading (with respect to
polymer)
Surface
m−1)
F1 2 wt% (50/50) + 10 wt% drug 30.4 ±
F2 2 wt% (75/25) + 10 wt% drug 32.1 ±
F3 4 wt% (50/50) + 5 wt% drug 28.9 ±
F4 4 wt% (75/25) + 5 wt% drug 28.4 ±
F5 2 wt% (50/50) 31.3 ±
F6 2 wt% (75/25) 28.2 ±
F7 4 wt% (50/50) 33.7 ±
F8 4 wt% (75/25) 34.5 ±ambient temperature. The mean value and standard deviation of ten
readings is reported. In order to investigate how PLGA copolymer ratio
and concentration inﬂuence the size,morphology and eventually the re-
lease proﬁle of the particles, four solutions with various PLGA concen-
trations (2 and 4 wt%), different copolymer ratios (50:50 and 75:25)
were prepared. Progesterone was added to each solution to make four
more solutions incorporating the drug. The measured values for these
parameters are summarized in Table 1.
2.4. Particle size and zeta potential
Particles were collected on glass slides and initially examined using
an optical microscope (Nikon EclipseME 600) ﬁttedwith a camera (Mi-
cropublisher 3.3 RTV, 3.3 megapixel CCD Color-BayerMosaic, Real Time
Viewing camera; Media Cybernetics, Marlow, UK). Particles were fur-
ther observed using a ﬁeld emission scanning electron microscope
(SEM; Hitachi) for particle size and morphology analysis. The micro-
graphs were taken from different areas for each sample and 300 parti-
cles were randomly chosen to measure both width and length using
ImageJ (Brocken Symmetry Software). To measure the zeta potential
of particles, a dilute suspension of particles was prepared in distilled
water. The zeta potential was estimated with ZetaPlus™ zeta potential
analyzer (Brookhaven Instruments, Holtsville, NY) at room temperature
on the basis of electrophoretic mobility under an electric ﬁeld. For each
formulation the mean value of 5 measurements were taken.sity, electrical conductivity and density the error was negligible.
tension (mN Viscosity (mPa
s)
Electrical conductivity (μS
cm−1)
Density (kg
l−1)
0.7 1.2 1.1 9.4
0.6 1.1 0.8 9.3
0.8 1.2 1.0 9.4
1.1 1.1 0.9 9.4
0.6 1.4 1.1 9.4
0.4 1.2 0.9 9.3
0.8 1.4 1.1 9.4
0.8 1.3 1.0 9.4
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The production yield of the processing technique was calculated as
the ratio of the mass of dried particles collected (Mc) to the theoretical
mass of particles sprayed during the collection time (Mi).
production yield %ð Þ ¼ Mc
Mi
 
 100% ð1Þ
Mi ¼ polymer concentration flow rate collection time ð2Þ
Drug encapsulation efﬁciency was determined by measuring the
amount of drug in the collected particles. Samples with 10 mg of
progesterone-loaded particles were weighed, dissolved with DMAc
(10 ml) and mechanically stirred for 400 s. The solution was then di-
luted 1:10 in DMAc: PBS (10: 90 v/v) and ﬁltered through 0.22 μm ﬁlter.
The drug content was analyzed using UV–visible spectrophotometer at
224 nm detection wave length. The concentration was then calculated
using a calibration equation.
Encapsulation Efficiency ¼ mass of actual drug loaded in particles
mass of drug used in particle fabrication
 100% ð3Þ
2.6. X-ray powder diffraction
XRPD patterns of samples were analyzed. The X-rays are generated
by a cathode ray tube ﬁltered to produce monochromatic radiation di-
rected towards the sample. Cu Kα radiation was used with wavelength
1.5418 Å and graphite monochromatic ﬁltering wave at a tube voltage
of 40 mV and tube current of 15 mA. The interaction of the incident
rayswith the sample produces constructive interference (and diffracted
rays). The diffracted intensity was recorded in the 2θ angle range from 5
to 40° at a scanning speed of 0.02°/min.
2.7. Fourier transform infrared spectroscopy
The infrared spectra of two PLGA formulations, progesterone and
drug-loaded particles, were recorded using a Fourier Transform Infrared
spectrophotometer. A small quantity of each samplewas placed onto the
sample holder and scanned in the frequency range of 400–4000 cm−1.
2.8. In vitro drug release of progesterone
To investigate the release proﬁle of progesterone-loaded particles,
in vitro dissolution studies were conducted in phosphate-buffered sa-
line (PBS) with pH 7.4. One compressed phosphate-buffer saline tablet
(PBS, yields 0.01 M phosphate buffer, 0.0027 M potassium chloride
and 0.137 M sodium chloride, pH 7.4 at 25 °C, Sigma-Aldrich, UK) was
dissolved in 200 ml of deionized water. 22 mg of progesterone-loaded
particles were encapsulated in a dissolvable polymer capsule. The
solubility of 2 mg of pure progesterone was investigated as a control
group under the same release conditions in order to investigate how
solubility of poorly water-soluble progesterone can be enhanced after
electrospraying in the PLGA matrix. The polymer capsule was then put
in a stainless-steel sinker basket. The sinker basket was subsequently
submerged into 100 ml PBS and the temperature of the solution was
kept constant at 37 °C. At predetermined time intervals, samples of
3 ml were withdrawn from each solution and immediately replaced
with fresh PBS already stored at 37 °C. Dissolution studies were also
conducted on pure progesterone under the same protocol as the control
group. The samples were ﬁltered through a membrane (0.22 μm) to ﬁl-
ter any impurities and avoid any interference in absorbance. Three rep-
licates of each sample were analyzed for drug concentration using UV–
visible spectrophotometer at 224nm to calculate the drug percentage. Acalibration equation to calculate the progesterone concentrations of un-
known sampleswas produced bymeasuring the absorbance of different
concentrations of progesterone from 1 to 20 μg/ml. The release studies
were conducted over 7 days and repeated three times for each set of
PLGA particles and the results of cumulative amount released was plot-
ted as a function of time.
2.9. Analytical model of drug release
The release of drugs from PLGA particles is known to be a compli-
cated process, involving both diffusion of the drug out of the particles
and inward diffusion of water leading to modiﬁcation of the PLGA. De-
tailed mathematical models of these processes have been set up
[47,48], and although they can be applied quite generally they have
most often been used with perfect sink boundary conditions, that is,
the drug concentration at the surface has been set to zero. In the exper-
iments reported here the drug solubility is low, and the solution in the
container is saturated after about 120 min and remains approximately
constant. In the saturation regime the rate of release of the drug will
be determined by the intervals between sampling the solution and
replenishing it rather than by the rate at which the drug can escape
from the particles.
During the early stages of release, it is reasonable to assume that
simple diffusion of the drug through the PLGA matrix is the rate-
controlling process. Under those circumstances a convenient approxi-
mation to the amount released after time t is given by the expression
[49]:
Q tð Þ ¼ Qmax tanh
β Dtð Þ12
a
 !
ð4Þ
where Qmax is the amount released at saturation, D is the diffusion coef-
ﬁcient of the drug in the PLGA, a is the radius of the particles, and β is a
ﬁtting parameter, equal to 3.345. Although Eq. (4) was derived for
spherical particles, it will also be a good approximation for the elon-
gated particles found in some of the experiments, as a similar expres-
sion has been found to be a good descriptor of release from long
tubes, where β is 2.257.
3. Results and discussion
3.1. Fabrication of microparticles
Four different formulations of drug-loaded particles and PLGA parti-
cles were successfully prepared using electrospraying under different
operating conditions (Table 2). The model drug, progesterone, was
encapsulated in PLGA polymers by co-dissolving in DMAc before
electropraying into ﬁne droplets. The effects of PLGA concentration
and copolymer compositionwere evaluated by particle characterization
and drug-release behavior in this study. Other important parameters
such as applied voltage and solution ﬂow rate were optimized to
achieve a stable cone-jet and uniform size distribution.
3.2. Characterization of microparticles
3.2.1. Particle size and geometry
3.2.1.1. Copolymer ratio and polymer/drug ratio. Particles were produced
both with and without progesterone to investigate the effects of poly-
mer/drug ratio and copolymer formulation of PLGA on particle size
andmorphology. Initially, drug free particles were produced as the con-
trol system using PLGA with two copolymer ratios (50:50 and 75:25),
and for each copolymer formulation, particles were prepared using
PLGA concentrations of 2 and 4 wt% (F5, F6, F7 and F8, respectively).
Drug free particles were generated at constant ﬂow rate of 3 μl/min
Table 2
Operating conditions tested and corresponding characterization. F2, F4, F6, and F8 particles are oblong and have two dimensions.
Formulations Processing Parameters Average Particle Dimensions (μm) Yield (%) Encapsulation Efﬁciency (%) Zeta Potential (mV)
F1 2 μl/min
12.6 kV
1.24 ± 0.21 81 ± 3 88 ±2 −44.60 ± 4.19
F2 2 μl/min
13.8 kV
1.21 ± 0.32
0.66 ± 0.09
83 ± 2 83 ±3 −43.01 ± 5.65
F3 2 μl/min
15.1 kV
0.72 ± 0.16 83 ± 2 83 ±3 −47.78 ± 3.85
F4 2 μl/min
15.7 kV
1.44 ± 0.2
0.63 ± 0.11
83 ± 2 83 ±3 −44.82 ± 3.49
F5 3 μl/min
15.3 kV
1.1 ± 0.18 85 ± 2 – −34.40 ± 3.87
F6 3 μl/min
15.8 kV
1.31 ± 0.37
0.64 ± 0.12
85 ± 1 – −35.87 ± 3.87
F7 3 μl/min
13.8 kV
1.43 ± 0.51 80 ± 1 – −38.39 ± 4.21
F8 3 μl/min
14 kV
1.66 ± 0.41
1.2 ± 0.33
84 ± 2 – −39.32 ± 3.34
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16.0 kV. The particles size andmorphologywere studied using SEM, and
the representative SEM images of each formulation are shown in Fig. 2.
In general, all particles were producedwith a smooth outer surface. The
results showed that both concentration and copolymer ratio of the poly-
mer inﬂuenced the diameter of progesterone-free and progesterone-
loaded particles. Larger particles were producedwith higher concentra-
tions of PLGA while the outer surface of the particles stayed smooth,
which can be attributed to the higher viscosity of the 4wt% polymer so-
lutions (values are shown in Table 1). The copolymer ratio and addition
of drug were found to have no signiﬁcant inﬂuence on particle size.
SEM images (Fig. 2) showed that the solution from PLGA copolymer
ratio of 50:50 for both polymer concentrations resulted in formation of
spherical particles, while solutions from PLA: PGA copolymer ratio of
75:25 produced elongated or irregular particles.
3.2.1.2. Flow rate and voltage. The size of the electrosprayed particles can
be tailored by changes in voltage and ﬂow rate. According to Hartman
and colleagues [50], reducing the polymer solution ﬂow rate reduces
particle size, as shown in Eqs. (5), (6), and (7).
d ¼ c ρε0Q
4
I2
 !1=6
ð5Þ
I∝ γκQð Þ1=2 ð6Þ
d∝Q1=2 ð7Þ
In Eqs. (5), (6), and (7) [50] d is the particle diameter (m), c is a con-
stant, Q the liquid ﬂow rate (m3 s−1), ρ the liquid density, I the current,
ε0 the permittivity of vacuum, γ the liquid surface tension in ambient
air, and κ the liquid electrical conductivity.
In order to investigate the effect of copolymer formulation on pro-
gesterone release proﬁle, particles obtained from the same polymer
concentration are required to have similar dimensions. Thus, ﬂow rate
was kept constant at 2 μl/min in order to achieve comparable particle
size distribution. The diameter of the particles obtained from all formu-
lations are in the range 0.72 and 1.66 μmand presented in Table 2, how-
ever note well that some are oblong in shape.
3.2.2. Zeta potential
Zeta potential is an important characteristic of polymeric particles, it
is a measurement of surface charge of the particles in a suspension. In a
sense, zeta potential can inﬂuence particle stability, as the absolute
value of zeta potential increases the amount of charge on the particle
surface. This results in larger electrostatic repulsive interaction betweenparticles which prevents the aggregation of the particles and leads to
the formation of more stable particles. A physically stable particle sus-
pension should have a minimum zeta potential of ±30 mV [51]. The
zeta potentials of all the formulations ranged between about−30 mV
and−50 mV. It showed slight increases in negativity with an increase
in polymer concentration and addition of drug. PLGA composition was
found to have no signiﬁcant inﬂuence on zeta potential.
3.2.3. X-ray diffraction
The physical form of the drug, polymer and drug-loaded particles
were tested using XRPD and the patterns are shown in Fig. 3. The
diffractogram of progesterone shows strong characteristic peaks at 2θ
values of 10.48, 12.64 and 16.9 degrees, which indicate that it is crystal-
line in its pure form. Both PLGA diffractograms have the characteristics
of amorphous material. Electrosprayed particles in all formulations
were tested, and no crystalline peaks were observed. A possible expla-
nation for this is that progesterone is molecularly dispersed within the
PLGA polymeric matrix and almost complete amorphization was
achieved.
3.2.4. Fourier transform infrared spectroscopy
FTIR spectra were used to detect whether there was any interaction
between PLGA and progesterone during the electrospray process. FTIR
spectra of progesterone, PLGA polymers (75:25 and 50:50) and
progesterone-loaded particles with different polymer/drug ratio are
shown in Fig. 4. The pure progesterone sample exhibited characteristic
peaks including bound OH (2800–3000 cm−1) and C_O stretching
(1600–1750 cm−1). PLGA polymers showed vibration C_O stretching
at 1752 cm−1 and C\\O stretching at 1000–1250 cm−1. Additionally,
weak peaks for C_O stretching were observed between 1600 and
1750 cm−1 in four different progesterone-loaded formulations, suggest-
ing the presence of intact progesterone. Thereby, the FTIR results indi-
cate that there were no chemical interactions between polymer and
progesterone.
3.3. In-vitro drug release study
Copolymer ratio is one of the key factors affecting the behavior of
drug release. By manipulating the copolymer ratio, the release kinetics
of the drug can be controlled. Fig. 5 shows cumulative percentages of re-
leased progesterone against time plots of electrosprayedmicroparticles
from four formulations. Narrow error bars indicate good reproducibility.
Progesterone release from all four formulations showed a biphasic re-
lease pattern. Phase I in this biphasic release proﬁle is usually described
as initial burst release, which can be due to three reasons: ﬁrst, drugs
that are freely and weakly bound on the particle surface, second, drug
release from the pores and cracks of particles with various morphology
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modelling analysis, phase I can also be described as diffusion dominated
release with a reasonable value for diffusion constant. Phase II isA)
B)
C)
10µm
10µm
10µm
D)
10µm
Fig. 2. SEM images and size distribution of drug-loaded particles producedwith constant proge
and h (F4, F6, F7 and F8, respectively).predominately governed by drug diffusion, either through water-ﬁlled
pores or polymer. The release study showed increase in PLA:PGA ratio
from 50:50 to 75:25 decreased the rate of progesterone release. Drug-sterone concentration of 2 mg/ml (a) F1, (b) F2, (c) F3, (d) F4 and drug-free particles e, f, g
E)
F)
G)
10µm
10µm
10µm
H)
10µm
Fig. 2 (continued).
63Y. Zhang et al. / Materials and Design 159 (2018) 57–67loaded PLGA particles of lower PLA:PGA ratio for both polymer concen-
trations (50:50 2 and 4 wt%) cumulatively released 862 and 792 μg in
2 h, respectively. On the other hand, higher copolymer ratio (75:25 2and 4 wt%) PLGA particles showed only 741 and 654 μg cumulative re-
lease in 2 h, respectively. For diffusion-controlled drug release, water-
uptake and swelling ability of polymer will potentially affect the
Fig. 3. XRPD patterns of a) progesterone, PLGA (75:25) and PLGA (50:50),
b) progesterone-loaded particle formulations F1, F2, F3 and F4.
Fig. 4. FTIR spectra of a) progesterone, PLGAs with different copolymer ratios (75:25 and
50:50) and b) electroprayed progesterone-loaded particles of four formulations.
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Fig. 5. Release proﬁle of progesterone from all formulations and progesterone dissolution
on its own.
64 Y. Zhang et al. / Materials and Design 159 (2018) 57–67diffusion rateswithin the polymermatrix. Increase in release rate on de-
creasing PLA:PGA ratio can be attributed to subsequent increase in hy-
drophilicity. Water-uptake and polymer hydration occurs immediately
upon immersion in water or administration in vivo [53]. Lower PLA:
PGA ratio (PLGA 50:50 vs. 75:25) is considered to be more hydrophilic
and thus water absorption rate might increase to a greater extent [54].
This action has been found to be a pore-forming process and leads to
an increase in drug diffusion [55,56]. Although, these pores are not big
enough for drug transport in the early stage of drug release, a porous
network will be established as more and larger pores formed [55,56].
For small hydrophobic drugs, transport through the polymer phase
may occur [54,57]. Progesterone is a small hydrophobic drugwith aver-
age molecular weight of 314.46 g mol−1 and low water solubility of
8.81 mg l−1 (25 °C) [58]. Since drug must enter the water phase before
it can be released, themore hydrophilic the polymer, the faster its water
absorption. Hence, PLGA particles with less lactide content, which is
therefore more hydrophilic, would provide a better environment for
drug to be released [52]. In case of PLGA particles of higher polymer con-
centration, about 70% of progesterone was released after 2 h, which is
before the onset of polymer dissolution. Some of the drug could have
been released due to being loosely attached to the surface, but it is un-
likely that only few of the drugmoleculeswould have been properly en-
capsulated in particles. Therefore, it is logical to assume that the release
of progesterone was dominated by diffusion through the polymer.In case of low drug loading (4 wt% PLGA+5 wt% progesterone), the
total amount of drug released after 2 h was less (792 μg) compared to
2 wt% PLGA drug-loaded particles (862 μg). For the other copolymer
composition (75:25) also, particles with relatively higher polymer con-
centration showed less cumulative drug release (654 μg) as compared
to the lower polymer concentration (741 μg). Besides, an increase in
the surface area: volume ratio results in higher release rate of hydro-
phobic drugs [18,59]. It was noticed that, with the increase in polymer
Table 3
Diffusion coefﬁcients D for progesterone in PLGA particles, deduced from ﬁtting the early
stage release to a simple diffusion model.
Formulation Size (μm) D (m2s−1)
F1 1.24 ± 0.21 (1.4 ± 0.4) × 10−17
F2 1.21 ± 0.32
0.66 ± 0.09
(1.5 ± 0.4) × 10−18
F3 0.72 ± 0.16 (6.8 ± 0.9) × 10−18
F4 1.44 ± 0.2
0.63 ± 0.11
(1.0 ± 0.3) × 10−18
65Y. Zhang et al. / Materials and Design 159 (2018) 57–67concentration, particle size increases resulting in decreased surface
area: volume ratio. Therefore, less buffer penetration andhence reduced
drug release rate occurs. Also, the increase in particle size may also re-
sult in increased drug diffusion distance, whichmay be another contrib-
uting factor. It was noticed that, the main difference was on the initial
burst release. The release proﬁle after 48 h in the same copolymer com-
position seems to have similar patterns. This indicates that after 48 h,
PLGA copolymer ratio is playing a dominating role.
It is observed that progesterone is not completely released from
most of the formulations during the 168 h of measurement, where
only 43, 50, 83 and 94% of progesterone was released from F1, F2, F3
and F4, respectively, indicating that there was still drug entrapped
within the polymer network. PLGA erosion typically does not occur
within 7 days and this explains the rest of drug within the polymer ma-
trix. As shown in Fig. 5 different progesterone release proﬁles have been
achieved using different PLGA copolymer ratios and concentrations. Ad-
ministration of progesterone by the oral delivery offers high compliance
for patient and is themost preferred route [60]. However, progesterone
suffers from low bioavailability and destruction in the digestive system
which take place faster than its absorption [61]. As observed, unlike en-
capsulated progesterone, pure progesterone molecules suffer from ex-
tremely low water solubility. As shown in Fig. 5, only 380 μg (24%)
progesterone has been dissolved, which is less than half of that from
all the other formulations. The dramatic increase in dissolution rate for
progesterone loaded PLGA formulations was partially explained by the
physical form change of progesterone (Fig. 3) after being electrosprayed
with PLGA into particles, which indicates that progesterone is molecu-
larly dispersed within the polymer matrix. As observed, about 85 and
76% of progesterone has been released from formulation F3 and F4 in
24 h, respectively, which can be desirable when rapid treatment is re-
quired and make it a preferable oral delivery system. A woman who
has her ovaries surgically removed will experience a sudden drop in
progesterone level. Such loss of hormone can lead to health problems
unless adequate hormone replacement is provided. In such a scenario,
rapid oral delivery of progesterone is preferred.
In formulations F1 and F2 only 43 and 37% of progesterone was re-
leased after 2 h, respectively, and about 50% was released after 7 days
of measurement. This release proﬁle of progesterone is beneﬁcial for
sustained release such as by depot injection. As mentioned previously,
progesterone has a role in maintaining pregnancy and preventing
preterm birth in women considered to be at high risk [6]. To date, the
most common routes of administration of progesterone are intramus-
cular injection and vaginal suppository [62]. In reference [62] the
suppository was made and characterized by a new process [63–65].
Progesterone delivered by regular injection may lead to inﬂammation
at the injection site, resulting pain, redness and sterile abscess. Yet,
the suppository material for vaginal delivery also has its limitationsFig. 6. Comparison of drug released from PLGAsuch as escaping from the vagina causing inconvenience and
uncertainty as to the drug dose absorbed. For women considered to be
at high risk of extremely preterm (b28 weeks) and very preterm
(28–32 weeks) delivery, long-term administration of progesterone is
required in order to maintain its level. Through depot injection [15],
the drug is slowly released from the deposits in a localizedmass.We be-
lieve that such an approach holds several potential beneﬁts including
that it ensures sustained release of progesterone at low doses over
prolonged periods and prevention of injection site problems by reduc-
ing the frequency of dosing. A depot injection is favorable for patients
who have difﬁculty swallowing medication or remembering to take
medication regularly.
In general, our data indicates that the electrosprayed polymeric
particles are beneﬁcial for formulation of poorly water-soluble drugs
for oral administration since they have great potential to enhance the
dissolution rate of the drug. The electrospraying process effects the
poorly aqueous-soluble molecules at the particulate level through
nanonization and amorphization [66]. Under the impact of electrical
forces, drugs are dispersed into small droplets ranging from micro- to
nanosize, which allows solvent to evaporate easily and, as a result, im-
mediate solidiﬁcation takes place. By virtue of rapid solvent evaporation
amorphous state of drug in the system is generated which attributed to
randomly “frozen” drug molecules in the solid polymer matrix forming
solid dispersion. Not only a predictable and controlled drug release can
be designed bymanipulating the polymer concentration and copolymer
ratio but also a protection of encapsulated active pharmaceutical ingre-
dients from degradation and loss of bioactivity.
3.4. Mathematical modelling
Wehave ﬁttedQ(t) in Eq. (4) to the experimental release rates up to
105 min, and the results are shown in Fig. 6. Using the particle sizes in
Table 2 we can extract diffusion coefﬁcients for progesterone in PLGA,
and the results are shown in Table 3. It appears that the diffusion coef-
ﬁcient in the 50:50 formulation is about ten times greater than in the
75:25 formulation. As a check of accuracy of these values, we haveparticles with analytical model predictions.
66 Y. Zhang et al. / Materials and Design 159 (2018) 57–67performed a similar analysis of previously published data [45], which
gave a graph showing the release proﬁles of progesterone from 50 μm
diameter 50 μmhighmicrosylinders of 50:50 PLGA. Fitting those results
gave a diffusion coefﬁcient of 2.1 × 10−17m2 s−1, which is in reasonable
agreement with our results from much smaller particles.
4. Conclusions
In this work, the release kinetics of hydrophobic drug (progester-
one) from drug/PLGA particles with different copolymer ratios and
polymer/drug ratiosweremeasured in vitro. It was found that the copol-
ymer composition and polymer/drug ratio inﬂuence drug release kinet-
ics at 37 °C. Overall, drug release rate was increased with increasing
polymer concentration and with an increase from the PLGA with
lower PLA: PGA copolymer ratio. In addition, this study also suggests
that hydrophobic drugs can be successfully encapsulated into PLGA par-
ticles using electrospraying and the dissolution property of hydrophobic
progesterone had been signiﬁcantly improved after electrospray which
can result in higher bioavailability. In conclusion, the drug release can be
controlled signiﬁcantly by varying the polymer concentration and co-
polymer composition for various applications.
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